Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vildagliptin vs Glibenclamide on EPCs in Type 2 Diabetes
NCT01822548Phase 3Completed
- Sponsor
- Azienda Ospedaliero-Universitaria di Parma
- Start
- Oct 2010
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of vildagliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Azienda Ospedaliero-Universitaria di Parma. Primary endpoint: Absolute Change in the Endothelial Progenitor Cell Number at 12 months. Started Oct 2010; status: completed.
02
Drugs
vildagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01822548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01822548.